Pathophysiology of concomitant atrial fibrillation and heart failure: Implications for management

Nature Clinical Practice Cardiovascular Medicine

Volumn 6, Issue 1, 2009, Pages 46-56

  Morrison, T Ben ^a   Bunch, T Jared ^b   Gersh, Bernard J ^a  

^a MAYO CLINIC   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; METOPROLOL TARTRATE; PLACEBO;

AGING; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DETERIORATION; DRUG WITHDRAWAL; EYE DISEASE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PROARRHYTHMIA; HUMAN; INOTROPISM; LIVER DISEASE; LUNG DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; THYROID DISEASE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DISEASE MODELS, ANIMAL; ELECTRIC COUNTERSHOCK; EVIDENCE-BASED MEDICINE; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART RATE; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 58049209668     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1414     Document Type: Review

References (71)

1. Tsang TS et al. (2003) The prevalence of atrial fibrillation of incident stroke cases and matched population controls in Rochester, Minnesota: Changes over three decades. J Am Coll Cardiol 42: 93-100
2. Wolf PA et al. (1996) Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J 131: 790-795
3. Levy D et al. (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397-1402
4. Wang TJ et al. (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 107: 2920-2925
5. Miyasaka Y et al. (2006) Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: A community-based study over two decades. Eur Heart J 27: 936-941
6. Fenelon G et al. (1996) Tachycardiomyopathy mechanisms and clinical implications. Pacing Clin Electrophyisol 19: 95-106
7. Olsson LG et al. (2006) Atrial. fibrillation and risk of clinical events in chronic heart failure with and without left ventricular dysfunction: Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47: 1997-2004
8. Grogan M et al. (1992) Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 69: 1570-1573
9. Ozcan C et al. (2003) Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. Am J Cardiol 92: 33-37
10. Redfield MM et al. (2000) Tachycardia-related cardiomyopathy: A common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 75: 790-795
11. Hsu LF et al. (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351: 2373-2383
12. Shinbane JS et al. (1997) Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 29: 709-715
13. Spinale FG et al. (1991) Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol Heart Circ Physiol 261: H308-H318
14. Tomita M et al. (1991) Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation 83: 635-644
15. 2+ channels in canine tachycardia-induced heart failure. Cardiovasc Res 49: 298-307
16. Spinale FG (1990) Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol Heart Circ Physiol 259: H218-H229
17. Wasmund SL et al. (2003) Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation 107: 2011-2015
18. Segerson NM et al. (2007) The effects of rate and irregularity on sympathetic nerve activity in human subjects. Heart Rhythm 4 20-26
19. Spinale FG et al. (1995) LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 268: H836-H847
20. Nerheim P et al. (2004) Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy. Circulation 110: 247-252
21. Benjamin EJ et al. (1994) Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA 271: 840-844
22. Ehrlich JR et al. (2002) Atrial fibrillation and congestive heart failure: Specific considerations at the intersection of the two common and important cardiac disease sets. J Cardiovasc Electrophysiol 13: 399-405
23. Li D et al. (2000) Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101: 2631-2638
24. Li D et al. (1999) Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 100: 87-95
25. 2+ channel abnormalities: Cause, consequence, or innocent bystander? Circ Res 85: 473-476
26. Amir O et al. (2008) Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol 102: 326-329
27. Tsang TS et al. (2001) Left atrial volume: Important risk marker of incident atrial fibrillation in 1,655 older men and women. Mayo Clin Proc 76: 467-475
28. Tsang TS et al. (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40: 1636-1644
29. Santinelli V et al. (2008) Atria. fibrillation progression in patients with and without lone atrial fibrillation. A five-year prospective follow-up study abstract [abstract]. J Am Coll Cardiol 51 (suppl A): A6
30. Jahangir A et al. (2007) Long-term progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 115: 3050-3056
31. Keating RJ et al. (2005) Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol 96: 1420-1424
32. Middlekauff HR et al. (1991) Prognostic significance of atrial fibrillation in advanced heart failure: A study of 390 patients. Circulation 84: 40-48
33. Dries DL et al. (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 32: 695-703
34. Swedberg K et al. (2005) Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: Results from COMET. Eur Heart J 26: 1303-1308
35. Pai RG et al. (2007) Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol 30: 349-354
36. Crijns HJ et al. (2000) Prognostic value of the presence of atrial fibrillation in patients with advanced heart failure. Eur Heart J 21: 1238-1245
37. Grönefeld GC et al. (2000) Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: Results from a prospective study. J Cardiovasc Electrophysiol 11: 1208-1214
38. Daubert JP et al. (2008) Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: Frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 51: 1357-1365
39. Bunch TJ et al. New onset atrial fibrillation in patients with an implantable cardioverter defibrillator is a strong risk marker of increased mortality from worsening cardiomyopathy. Heart Rhythm, in press
40. Miyasaka Y et al. (2007) Coronary ischemic events after first atrial fibrillation: Risk and survival. Am J Med 120: 357-363
41. Wolf PA et al. (1991) Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22: 983-988
42. Hunt SA et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235
43. Anand K et al. (2006) Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 152: 217-222
44. Li D et al. (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104: 2608-2614
45. van Veldhuisen DJ et al. (2006) Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF study. Eur J Heart Fail 8: 539-546
46. Joglar JA et al. (2001) Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 142: 498-501
47. Khand AU et al. (2003) Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42: 1944-1951
48. Fuster V et al. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: E257-e354
49. Delle Karth G et al. (2001) Amiodarone versus diltiazem for rate control in critically ill patients with tachyarrhythmias. Crit Care Med 29: 1149-1153
50. Hohnloser SH et al. (2000) Rhythm or rate control in atrial fibrillation - Pharmacological. Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 356: 1789-1794
51. Freudenberger RS et al. (2007) Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol 100: 247-252
52. Deedwania PC et al. (1998) Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans vffairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98: 2574-2579
53. Hagens VE et al. (2005) Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the rate control versus electrical cardioversion (RACE) study. Am Heart J 149: 1106-1111
54. Wyse DG et al. (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 1825-1833
55. Corley SD et al. (2004) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 109: 1509-1513
56. Pedersen OD et al. (2001) Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish Investigations of Arrhythmia and Mortality On Dofetilide (DIAMOND) substudy. Circulation 104: 292-296
57. Torp-Pedersen C et al. (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341: 857-865
58. Singh BN et al. (2005) Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352: 1861-1872
59. Roy D et al. (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358: 2667-2677
60. Pratt CM et al. (2004) The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival. Evaluation (ALIVE) trial. J Am Coll Cardiol 43: 1211-1216
61. Hohnloser SH et al. (2008) A placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter (AF/AFL). Heart Rhythm Society 2008 Scientific Sessions: 2008 May 14-17, San Francisco, CA, USA
62. Kober L et al. for the Dronedarone Study Group (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358: 2678-2687
63. Brignole M et al. (1998) Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: A randomized, controlled study. Circulation 98: 953-960
64. Doshi RN et al. (2005) Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 16: 1160-1165
65. Hoppe UC et al. (2006) Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114: 18-25
66. Hamdan MH et al. (2006) Atrioventricular junction ablation followed by resynchronization therapy in patients with congestive heart failure and atrial fibrillation (AVERT-AF) study design. Pacing Clin Electrophysiol 29: 1081-1088
67. Gentlesk PJ et al. (2007) Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 18: 9-14
68. Khan MN et al. (2006) Late-breaking clinical trial abstracts from the American Heart Association's Scientific Sessions 2006: Randomized controlled trial of pulmonary vein antrum isolation vs. AV node ablation with bi-ventricular pacing for treatment of atrial fibrillation in patients with congestive heart failure (PABA CHF) [abstract]. Circulation 114: 2426
69. Stulak JM et al. (2006) Left ventricular dysfunction in atrial fibrillation: Restoration of sinus rhythm by the Cox-Maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 82: 494-500
70. Adabag AS et al. (2007) Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 154: 1140-1145
71. Nigam TKL et al. (2007) Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 116: 2101-2109